Immunotherapy

Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.

Mario Sznol, MD, from Yale University, discusses where the field of immune-oncology will be 1 and 5 years from now at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.

A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers.

A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma.

A look at the latest lung cancer research, recent advances in the field and their clinical applications.

Immune checkpoint inhibitors have demonstrated impressive activity in patients with CRC and other solid tumors that are dMMR. Researchers explore the data. 

This year has seen many advances in immunotherapy. Here is a look at some of the most significant research. 

The VOLFI trial enrolled 105 patients with RAS wild-type metastatic colorectal cancer.

Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease.

A review of recent advances in the noninvasive imaging of immunotherapeutic targets.

Over that time, the number of active drugs in development has grown by more than 90%.

While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.

A total of 30 patients were enrolled in an expansion cohort for relapsed/refractory primary mediastinal B-cell lymphoma and received nivolumab and brentuximab vedotin.

Atezolizumab is an immune-checkpoint inhibitor, which has been approved by the US Food and Drug Administration (FDA) in various combinations for a number of cancer types in recent years.

 The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events  that have proven to be extremely challenging to manage.

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

A study in JAMA Oncology evaluated re-administration of immune checkpoint blockade in cancer patients who experienced a grade 2 or higher immune-related adverse event.

A review and meta-analysis in JAMA Oncology evaluated the incidence of treatment-related adverse events in patients receiving PD-1 or PD-L1 therapy.

The phase II KEYNOTE-158 basket trial evaluated single-agent pembrolizumab in patients with previously treated advanced cervical cancer.

Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.

A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.

Experts shared the challenges they've encountered in integrating novel treatments such as CAR T-cell therapy into practice at the 2019 NCCN Annual Conference.

A systematic review in JAMA Oncology examined the safety and efficacy of immune checkpoint inhibitors in advanced-stage cancer patients with HIV infection.

The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.